The first quarter of 2026 saw a resurgence in high-impact short seller reports, with firms targeting companies based on alleged accounting irregularities and governance failures. Notably, Gotham City Research’s report on Carvana alleged that the company overstated its 2023–2024 earnings by over $1 billion, citing excessive reliance on related-party transactions involving the Garcia family. Similarly, ADMA Biologics experienced a 15% share price decline following a report that challenged its growth narrative and financial reporting. These events highlight a recurring theme in forensic research: the vulnerability of companies with complex revenue recognition or opaque related-party structures. Unlike the 'short-and-distort' cases currently being prosecuted by the DOJ, these reports focus on fundamental forensic accounting discrepancies. The market's sensitivity to these reports suggests that investors are increasingly wary of management credibility in a high-interest-rate environment. When a short seller successfully identifies a disconnect between a company’s reported growth and its underlying cash flow or governance, the resulting volatility is often swift and severe. For institutional investors, these reports serve as a reminder that 'narrative-driven' stocks are particularly susceptible to forensic scrutiny. The trend indicates that short sellers are moving away from purely speculative attacks and toward deep-dive accounting analysis, which historically carries more weight with regulators and the broader market.
Original reporting by LevelFields. This article is desk analysis prepared by The Forensic Ledger from publicly available sources, summarized with citation to the original.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.
